Evidence map›Paper›PMID 26807121›Full record

ArticleNeural regeneration research2015

Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone.

Xiao-Lin Hou, Yan Chen, Hua Yin, Wei-Gang Duan

Open access · goldAbstract read
In one paragraph

Article in Neural regeneration research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xiao-Lin HouKey Laboratory of Molecular Biology for Sinomedicine, Yunnan Key Laboratory for Enthnomedicine, Kunming, Yunnan Province, China.
Yan ChenKey Laboratory of Molecular Biology for Sinomedicine, Yunnan Key Laboratory for Enthnomedicine, Kunming, Yunnan Province, China.
Hua YinKey Laboratory of Molecular Biology for Sinomedicine, Yunnan Key Laboratory for Enthnomedicine, Kunming, Yunnan Province, China.
Wei-Gang DuanKey Laboratory of Molecular Biology for Sinomedicine, Yunnan Key Laboratory for Enthnomedicine, Kunming, Yunnan Province, China; Initiative Team of Microenvironment, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan Province, China.ORCID 0000-0002-9006-861X
Yunnan University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance mechanisms of rho-associated kinase (ROCK) inhibitors are associated with the enhanced expression of cyclooxygenase-2 (COX-2). The therapeutic effects of ROCK on nervous system diseases might be enhanced by COX-2 inhibitors. This study investigated the synergistic effect of the combined use of the ROCK inhibitor fasudil and a COX-2 inhibitor celecoxib on spinal cord injury in a rat model established by transecting the right half of the spinal cord at T11. Rat models were orally administrated with celecoxib (20 mg/kg) and/or intramuscularly with fasudil (10 mg/kg) for 2 weeks. Results demonstrated that the combined use of celecoxib and fasudil significantly decreased COX-2 and Rho kinase II expression surrounding the lesion site in rats with spinal cord injury, improved the pathomorphology of the injured spinal cord, and promoted the recovery of motor function. Moreover, the effects of the drug combination were better than celecoxib or fasudil alone. This study demonstrated that the combined use of fasudil and celecoxib synergistically enhanced the functional recovery of injured spinal cord in rats.

Indexed as

celecoxibcyclooxygenase-2fasudilnerve regenerationneural regenerationNSFC grantRho kinasespinal cord injury

Identifiers

PMID26807121
PMCPMC4705798
OpenAlexW2282091730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.